371 related articles for article (PubMed ID: 9301500)
1. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group.
Campieri M; Ferguson A; Doe W; Persson T; Nilsson LG
Gut; 1997 Aug; 41(2):209-14. PubMed ID: 9301500
[TBL] [Abstract][Full Text] [Related]
2. A comparison of budesonide with prednisolone for active Crohn's disease.
Rutgeerts P; Löfberg R; Malchow H; Lamers C; Olaison G; Jewell D; Danielsson A; Goebell H; Thomsen OO; Lorenz-Meyer H
N Engl J Med; 1994 Sep; 331(13):842-5. PubMed ID: 8078530
[TBL] [Abstract][Full Text] [Related]
3. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.
Escher JC;
Eur J Gastroenterol Hepatol; 2004 Jan; 16(1):47-54. PubMed ID: 15095852
[TBL] [Abstract][Full Text] [Related]
4. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
N Engl J Med; 1994 Sep; 331(13):836-41. PubMed ID: 8078529
[TBL] [Abstract][Full Text] [Related]
5. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
6. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group.
Greenberg GR; Feagan BG; Martin F; Sutherland LR; Thomson AB; Williams CN; Nilsson LG; Persson T
Gastroenterology; 1996 Jan; 110(1):45-51. PubMed ID: 8536887
[TBL] [Abstract][Full Text] [Related]
7. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease.
Cortot A; Colombel JF; Rutgeerts P; Lauritsen K; Malchow H; Hämling J; Winter T; Van Gossum A ; Persson T; Pettersson E
Gut; 2001 Feb; 48(2):186-90. PubMed ID: 11156638
[TBL] [Abstract][Full Text] [Related]
8. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease.
Schoon EJ; Bollani S; Mills PR; Israeli E; Felsenberg D; Ljunghall S; Persson T; Haptén-White L; Graffner H; Bianchi Porro G; Vatn M; Stockbrügger RW;
Clin Gastroenterol Hepatol; 2005 Feb; 3(2):113-21. PubMed ID: 15704045
[TBL] [Abstract][Full Text] [Related]
10. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
11. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM; McTavish D
Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
[TBL] [Abstract][Full Text] [Related]
12. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
13. Treatment of joint pain in Crohn's patients with budesonide controlled ileal release.
Florin TH; Graffner H; Nilsson LG; Persson T
Clin Exp Pharmacol Physiol; 2000 Apr; 27(4):295-8. PubMed ID: 10779128
[TBL] [Abstract][Full Text] [Related]
14. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
15. Oral budesonide in active Crohn's disease.
Löfberg R; Danielsson A; Salde L
Aliment Pharmacol Ther; 1993 Dec; 7(6):611-6. PubMed ID: 8161666
[TBL] [Abstract][Full Text] [Related]
16. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
17. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
Löfberg R; Rutgeerts P; Malchow H; Lamers C; Danielsson A; Olaison G; Jewell D; Ostergaard Thomsen O; Lorenz-Meyer H; Goebell H; Hodgson H; Persson T; Seidegård C
Gut; 1996 Jul; 39(1):82-6. PubMed ID: 8881815
[TBL] [Abstract][Full Text] [Related]
18. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
19. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
[TBL] [Abstract][Full Text] [Related]
20. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules.
Green JR; Lobo AJ; Giaffer M; Travis S; Watkins HC;
Aliment Pharmacol Ther; 2001 Sep; 15(9):1331-41. PubMed ID: 11552903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
